TCRT — Alaunos Therapeutics, Inc. - Common Stock
Session close: $3.03. Regular-session share volume: 169,457,810. Change from previous close: +188.57%.
Key developments
Alaunos acquired Velaris Therapeutics, bringing a portfolio focused on pulmonary arterial hypertension and related cardiopulmonary conditions. The reporting linked the session's sharp advance to this transaction and its accompanying financing. The acquired ligand traps and complementary biologics aim to address signaling imbalances involved in pulmonary vascular remodeling, giving Alaunos additional therapeutic programs to develop.
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Alongside the acquisition, Alaunos completed a private placement of nonvoting convertible preferred stock. Management expects the proceeds to provide a multiyear operating runway, funding proof-of-concept work for the lead ligand trap and an antibody program while supporting early regulatory submissions for additional candidates. That funding supports the reported development plans, although the runway remains management's expectation rather than an assured outcome.
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
The pipeline combines approaches within and beyond activin signaling. Its lead candidate seeks to reproduce established pharmacology while improving the therapeutic profile; other ligand traps were designed to spare ligands associated with adverse hematologic events. A complementary antibody targets an alternative disease pathway, with standalone and combination use envisioned. These are development objectives, not demonstrated clinical benefits in the supplied evidence.
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Paragon also added former Apogee executives whose prior work included advancing Paragon-discovered assets into clinical development. Their stated remit covers Paragon's proprietary assets and new ventures, beginning with Velaris. This provides relevant development experience around the acquired business, but the article describes appointments at Paragon rather than a direct replacement of Alaunos management.
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Separate market reports recorded Alaunos gains before the opening bell and during regular trading. The detailed acquisition report was also published intraday, so the supplied coverage does not establish the closing outcome. The market roundups provide trading context rather than additional business explanations, and none of the articles supplies an explicitly dated future company event.
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday? · 12 Health Care Stocks Moving In Tuesday's Intraday Session · 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
News sources
Company news Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday? · Company news Alaunos Therapeutics Shares Resume Trade · Company news Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics · Company news Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.